Posted in M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war March 26, 2026 BioPharma Dive Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run. M&A / DealsRead full story